3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
5
Unspecified Adult Solid Tumor, Protocol Specific
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Ovarian Neoplasms
1
Neoplasms
1
Meningeal Carcinomatosis
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Brain Neoplasms
1
Interventions
pembrolizumab
82
Paclitaxel
71
Gemcitabine
66
Carboplatin
61
Cisplatin
46
Docetaxel
44
Bevacizumab
41
Nivolumab
33
Irinotecan
31
Fluorouracil
29
Pemetrexed
28
Cyclophosphamide
26
Cetuximab
26
Capecitabine
26
Erlotinib Hydrochloride
22
venetoclax
21
trametinib
21
Leucovorin
20
Sorafenib
17
Albumin-Bound Paclitaxel
17
Afatinib
17
130-nm albumin-bound paclitaxel
17
Topotecan
16
Radiotherapy
16
Oxaliplatin
16
fludarabine
15
regorafenib
14
budigalimab
14
atezolizumab
14
Ipilimumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms
×
peginterferon alfa-2b
×
Clear all
NCT03554005
2019-07-15
MK-4031-009
Merck Sharp & Dohme LLC
Phase 1
Completed
29 enrolled
11 charts